Amarillo Biosciences Issues Progress Report

AMARILLO, TX--(Marketwire - November 09, 2010) -

Amarillo Biosciences, Inc. (ABI) (OTCBB: AMAR) today issued the following Progress Report:

• Hepatitis C: CytoPharm, Inc., ABI’s strategic partner in Taiwan is funding a Phase 2 clinical trial of 165 patients with chronic hepatitis C virus infection. As of the end of October 2010, 124 patients have already been enrolled with full enrollment expected by early 2011. The aim of the trial is to reduce the virologic relapse rate for those patients who have completed the standard combination therapy for hepatitis C, which consists of high dose injectable interferon alpha and Ribavirin. Although most patients respond to the standard therapy, up to 50% of those with certain viral genotypes relapse after treatment. Patients in the study will receive one of two different daily doses of ABI’s human interferon alpha lozenges or placebo for 24 weeks, followed by untreated observation for 24 weeks to check for relapse. Preliminary results from this important study are expected to be available before the end of next year.

• Influenza: In addition to its hepatitis C study, CytoPharm will be funding a study of ABI’s interferon-alpha lozenges in the treatment of influenza. The study, which has been approved by the Taiwanese Department of Health, will start in January 2011. Half of the patients with confirmed influenza A infection will be assigned to 5 days of twice daily treatment with interferon lozenges and half will receive placebo. All of the patients will also receive standard treatment with Tamiflu. The aim of the study is to determine if the combination of Tamiflu plus oral interferon is superior to Tamiflu alone in the treatment of influenza.

• Scientific journal publication on interferon and influenza: The Company’s technology will be featured in an upcoming issue of the scientific journal, Expert Opinion on Biological Therapy (EOBT). The editors of the EOBT independently commissioned Dr. Manfred Beilharz to write a review article, which is titled: “Low dose oral interferon alpha: has its time finally come?” This article discusses the various studies in which ABI’s low dose interferon-alpha lozenges has been used to successfully treat various human diseases, with a focus on influenza. Dr. Beilharz was one of the investigators of a study in which the Company’s interferon-alpha lozenges were found to reduce the incidence of moderate to severe febrile acute respiratory illness (i.e. cold/flu with a fever) when taken daily by healthy volunteers during the winter cold/flu season in Australia.

About Amarillo Biosciences
Amarillo Biosciences, Inc. is a U.S. biotechnology firm operating in global partnership with the Hayashibara Group, which also holds 5.4% of Amarillo Biosciences shares and has provided over $18 million in loans, grants and equity investments. The Company’s primary focus is extensive and ongoing R&D into the use of low-dose, orally administered interferon as a treatment for a variety of conditions, including influenza, hepatitis C, chronic cough, and opportunistic infections in patients who are HIV positive. The Company has invested nearly $40 million to establish oral interferon as a therapeutic agent. The majority of those funds were invested in clinical trials in an effort to achieve FDA approval for interferon. Additional information is available on the web at http://www.amarbio.com/.

Except for the historical information contained herein, the matters discussed in this news release are forward-looking statements that involve risks and uncertainties, including uncertainties related to product development, uncertainties related to the need for regulatory and other government approvals, dependence on proprietary technology, uncertainty of market acceptance of oral interferon or the Company’s other product candidates and other risks detailed from time to time in the Company’s filings with the Securities and Exchange Commission. In particular, see “Item 1. Description of Business” and “Item 7A. Qualitative and Quantitative Disclosures About Market Risk” of the Company’s Form 10-K for the fiscal year ended December 31, 2009.